Oncology Corporate Profile
Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft-versus-host disease (GVHD).
Website: http://www.bellicum.com/
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| BPX-501 | adjunct T-cell therapy | Acute Myelogenous Leukemia (AML) | I | |
| BPX-501 | adjunct T-cell therapy | Pediatric Acute Lymphocytic Leukemia (ALL) | I | |
| BPX-501 | adjunct T-cell therapy | Various cancer types | I | |
| BPX-701 | T-cell receptor | Acute Myelogenous Leukemia (AML) | Preclinical | |
| CD19 | CAR-T cell therapy | Leukemia | Preclinical | |
| CD19 | CAR-T cell therapy | Lymphoma | Preclinical | |
| BPX-701 | T-cell receptor | Myelodysplastic Syndrome (MDS) | Preclinical | |
| CD19 | CAR-T cell therapy | Pediatric Acute Lymphocytic Leukemia (ALL) | Preclinical | |
| BPX-601 | inducible MyD88/CD40 activiation molecule | Prostate cancer | Preclinical | |
| BPX-701 | T-cell receptor | Various cancer types | Preclinical |
View additional information on product candidates here »
